Allogene Therapeutics, Inc. is downgraded from Strong Buy to Hold due to setbacks in its pivotal phase 2 ALPHA3 trial. ALLO's cema-cel for Large B-Cell Lymphoma remains on track for a key futility ...
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the ...
A high frequency of T cells are alloreactive and are involved in transplant rejection and graft-versus-host disease (GVHD). Many alloreactive T cells are much more peptide specific than previously ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback